DIS' discounted valuation, rising earnings outlook and IP-driven growth support a hold despite international parks weakness and market underperformance.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MPC's 138.6% YTD surge is backed by strong refining execution, high-return projects and robust cash flow, though cyclical risks remain.
SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.
Snowflake TodaySNOWSnowflake$352.26 -4.21 (-1.18%) As of 10:55 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$118.30▼$384.56Price Target$414.24Add to WatchlistSnowflake's NASDAQ: SNOW stock surged more than 20% following its Q2 fiscal year 2027 (FY2027) release because of the guidance, and it could continue to rise because of what's to come.
American technology microcap AIxCrypto Holdings (AIXC) is fully liquidating its digital asset portfolio and winding down its crypto treasury strategy.
lululemon athletica inc. faces intensifying revenue declines, missing Q2 estimates and guiding for its first full-year revenue drop since going public. Americas weakness deepened with 8% revenue and 12% comp sales declines; international growth stalled, notably with China revenues down 2%. Q2 EPS beat was driven by $134.5M in tariff refunds, masking underlying margin and profitability deterioration.
Gold fell almost $100 on Friday following surprise surge in US nonfarm payrolls that eased worries of US policymakers and boosted expectations of rate hike on Sep 16 policy meeting.
Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its shares. The broker said Hikma's recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business.
Gold hit the target of 4450-72 to break above it. As we see from the chart, the market faces support at the 4440-60 zone, and if prices remain above it, the advance movement could sustain towards the second target at 4545-65.
Intraday levels show possible support around 1.3475 which could support the market in the short-term. As we see from the chart, prices face supports at 1.3475 and 1.3400 where each support could lead to an advance toward 1.3675.
USDJPY resumed the drop to test the support at 155.00-20 yesterday. As we see over the chart, the support at 155.00-20 could lead to a rebound with resistance at 157.40.
The Euro hit a correction towards the target and support of 1.1570. As we see from the chart and as long as the market holds above this support, a rebound towards 1.1710 is likely.
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Airbus maintains its market leadership with over 1,000 net orders year-to-date, despite ongoing production ramp-up challenges. July deliveries were flat year-on-year at 67 units, with A330 deliveries paused due to a foreign object issue, now resolved. EADSF's book-to-bill ratio remains robust at 2.6x year-to-date, reflecting strong demand and order inflow across both single-aisle and wide-body segments.
Adobe shares ADBE fell nearly 7% on Friday after the software company announced a leadership transition on Thursday. Anil Chakravarthy, president of Adobe's Customer Experience Orchestration business, will become president and chief executive officer on Dec. 1, 2026.
Credo grew Q1 revenue 115% to $479 million while sustaining 68% gross margin and 49.3% non GAAP net margin. Management expects FY2027 revenue growth above 85%, with optical revenue exceeding $600 million as a second growth engine emerges. DustPhotonics expands Credo across silicon photonics, 800G, 1.6T and NPO, creating multiple opportunities to increase content per connection.
Stevenson cautions that the trend must persist across different market conditions before it can be viewed as a durable shift.
LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.
Gold Weekly Forecast: Fed uncertainty caps the upside